| Literature DB >> 33624533 |
Seyed H Shahcheraghi1,2, Jamshid Ayatollahi1, Alaa Aa Aljabali3, Madhur D Shastri4, Shakti D Shukla5, Dinesh K Chellappan6, Niraj K Jha7, Krishnan Anand8, Naresh K Katari9, Meenu Mehta10,11, Saurabh Satija10,11, Harish Dureja12, Vijay Mishra11, Abdulmajeed G Almutary13, Abdullah M Alnuqaydan13, Nitin Charbe14, Parteek Prasher15, Gaurav Gupta16, Kamal Dua10, Marzieh Lotfi2,17, Hamid A Bakshi18, Murtaza M Tambuwala18.
Abstract
The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.Entities:
Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2
Mesh：
Substances：
Year: 2021 PMID： 33624533 PMCID： PMC7923686 DOI： 10.4155/tde-2020-0129
Source DB: PubMed Journal: Ther Deliv ISSN： 2041-5990